Robert Dillard

Cancer Nursing Today nonprod

A prognostic model can be used to determine the efficacy of radiotherapy in combination with chemotherapy in treating metastatic non-small cell lung cancer (NSCLC), according to a study published in Frontiers in Oncology.In this study, researchers retrospectively reviewed 243 patients with metastatic NSCLC in two prospective studies. They then developed a prognostic model based on the results of a Cox regression analysis.According to the results,&nbsp;the following factors independently predicted poor overall survival (OS): male sex; Karnofsky Performance Status score &lt;80; &lt;4 chemotherapy cycles; hemoglobin level ?120 g/L; neutrophil count &gt;5.8&times;109/L; and platelet count &gt;220&times;109/L. Patients were further divided into one of three risk groups: those having two or fewer risk factors were scored as the low-risk group, those having three risk factors were scored as the moderate-risk group, and those having four or more risk factors were scored as the high-risk group.The results showed that in the low-risk group, the one-year OS was 67.7%, two-year OS was 32.1%, and three-year OS was 19.3%; in the moderate-risk group, one-year OS was 59.6%, two-year OS was 18.0%, and three-year OS was 7.9%. The OS rates for the high-risk group were 26.2%, 7.9%, and 0%, respectively.&ldquo;[Patients with] metastatic NSCLC treated with chemotherapy in combination with thoracic radiation may be classified as low-risk, moderate-risk, or high-risk group using six independent prognostic factors. This prognostic model may help design the study and develop the plans of individualized treatment,&rdquo; the researchers concluded.

Prognostic Model Predicts Overall Survival for Metastatic Non-Small Cell Lung Cancer

Lung Cancer

A prognostic model can be used to determine the efficacy of radiotherapy in combination with chemotherapy in treating metastatic non-small cell lung cancer (NSCLC), according to a study published in Frontiers in Oncology. In this study, researchers retrospectively reviewed 243 patients with metastatic NSCLC in two prospective studies. They then developed a prognostic model based [...]

About Us

Editorial Policy

Authors

Advertising

eNewsletters

Contact Us

Contribute

Calendar of Events

Career Center

Blood Cancers Today

GU Oncology Now

DocWire News

MashupMD

Urban Health Today

Breast Cancer

Colorectal Cancer

GI Cancer

GU Cancer

Gynecologic Cancer Awareness Month

Gyn-Onc

Blood Cancer Awareness Month

GVHD

Leukemia

Lymphoma

Myeloproliferative Neoplasms

Multiple Myeloma

Myelodysplastic Syndrome

Myelofibrosis

Sickle Cell

Hem/Onc

Professional Development

Patient Voice

Skin Cancer

Other Tumor Types

News

Treatment

More

Conferences

Calendar

CARE Award

Best Practices

Expert Interviews

Subscribe